Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label, Multi-Center Phase I Study of Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) Monoclonal Antibody KHK2866 as Monotherapy in Subjects with Advanced Solid Tumors and in Combination with Chemotherapy for Epithelial Ovarian, Extra-Ovarian Primary Peritoneal, or Fallopian Tube Cancer.

X
Trial Profile

Open-Label, Multi-Center Phase I Study of Anti-Heparin-Binding Epidermal Growth Factor-Like Growth Factor (HB-EGF) Monoclonal Antibody KHK2866 as Monotherapy in Subjects with Advanced Solid Tumors and in Combination with Chemotherapy for Epithelial Ovarian, Extra-Ovarian Primary Peritoneal, or Fallopian Tube Cancer.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 02 May 2024

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs KHK 2866 (Primary) ; Carboplatin; Doxorubicin liposomal; Gemcitabine; Paclitaxel
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Solid tumours
  • Focus Adverse reactions
  • Most Recent Events

    • 27 Oct 2015 Results published in the Targeted Oncology
    • 01 Nov 2012 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 29 Oct 2012 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top